Fintel reports that GIC Private has filed a 13G form with the SEC disclosing ownership of 2.20MM shares of Regenxbio Inc (RGNX). This represents 5.1% of the company. In their previous filing dated ...

RegenXBio Inc. ($RGNX) announced an update on their ongoing clinical study. RegenXBio Inc. is conducting a Phase 3 clinical study titled ‘A Phase ...

Good day, and thank you for standing by. Welcome to the REGENXBIO Inc. First Quarter 2023 Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would ...

Baird has initiated coverage on RegenXbio Inc RGNX with an Outperform rating and a price target of $42. The analyst writes that Regenx has one of the most broad approaches to AAV-based gene therapies.

Welcome everyone to the Fourth Quarter and Year End 2024 REGENXBIO Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a ...

ROCKVILLE, Md., Nov. 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the third quarter ended September 30, 2023, and recent operational highlights, ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44th Annual J.P. Morgan Healthcare Conference.

A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days ...

REGENXBIO Inc. (NASDAQ:RGNX) stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy. The Details: The company announced that it has dosed ...

REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy.

Charles Schwab Investment Management Inc. reduced its stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 16.3% in the 4th quarter, according to the company in its most recent filing with the SEC.